Using pharmacokinetic principles to optimize pain therapy

Nature Reviews Rheumatology

Volumn 6, Issue 10, 2010, Pages 589-598

  Brune, Kay ^a   Renner, Bertold ^a   Hinz, Burkhard ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENOXAPROFEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; ETORICOXIB; IBUPROFEN; ISOXICAM; KETOPROFEN; LORNOXICAM; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; OMEPRAZOLE; OXYPHENBUTAZONE; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROPYPHENAZONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB; TENOXICAM; VALDECOXIB;

ANALGESIC ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; HEART INFARCTION; HOMEOSTASIS; HUMAN; INCIDENCE; INFLAMMATION; INTESTINE ULCER; LIVER TOXICITY; LOW DRUG DOSE; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; STROKE; TARGET ORGAN; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR DISEASE;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG TOXICITY; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 77957581404     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.141     Document Type: Review

References (78)

1. Hughes, D. A. & Aronson, J. K. A systematic review and empirical analysis of the relation between dose and duration of drug action. J. Clin. Pharmacol. 50, 17-26 (2010).
2. Greenblatt, D. J. Elimination half-life of drugs: value and limitations. Annu. Rev. Med. 36, 421-427 (1985).
3. Levy, G. & Gibaldi, M. Pharmacokinetics of drug action. Annu. Rev. Pharmacol. 12, 85-98 (1972).
4. Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A. & Needleman, P The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265, 16737-16740 (1990)
5. Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 2692-2696 (1991).
6. 2 selectively bl ocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci. 5, 34-40 (2002).
7. Zeilhofer, H. U. Prostanoids in nociception and pain. Biochem. Pharmacol. 73, 165-174 (2007).
8. Grosser, T., Fries, S. & FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest 116, 4-15 (2006).
9. Patrono, C. & Baigent, C. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol. Interv. 9, 31-39 (2009).
10. Hinz, B. & Brune, K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol. Sci. 29, 391-397 (2008).
11. Aronoff, D. M., Boutaud, O., Marnett, L. J. & Oates, J. A. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. J. Pharmacol. Exp. Ther. 304, 589-595 (2003).
12. Palmer, J. D., Sparrow, O. C. & Iannotti, F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 35, 1061-1064 (1994).
13. Huntjens, D. R., Danhof, M. & Della Pasqua, O. E. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 nhibitors. Rheumatology (Oxford) 44, 846-859 (2005).
14. Capone, M. L. et al. Pharmacodynamic nteraction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 45, 1295-1301 (2005).
15. Catella-Lawson, F. et al. Cyclooxygenase nhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345, 1809-1817 (2001).
16. MacDonald, T. M. & Wei, L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361, 573-574 (2003).
17. US Department of Health and Human Services Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/ucm125222.htm (2006).
18. Wilner, K. D. et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol. 42, 1027-1030 (2002).
19. Gladding, P A. et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol. 101, 1060-1063 (2008).
20. Greenberg, H. E. et al. A new cyclooxygenase-2 nhibitor, rofecoxib (vIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J. Clin. Pharmacol. 40, 1509-1515 (2000).
21. Dallob, A. et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. 43, 573-585 (2003).
22. Ouellet, M., Riendeau, D. & Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl Acad. Sci. USA 98, 14583-14588 (2001).
23. Rimon, G. et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl Acad. Sci. USA 107, 28-33 (2010).
24. Brune, K. & Hinz, B. Selective cyclooxygenase-2 nhibitors: similarities and differences. Scand. J. Rheumatol. 33, 1-6 (2004).
25. Hinz, B., Renner, B. & Brune, K. Drug insight: cyclo-oxygenase-2 inhibitors-a critical appraisal. Nat Clin. Pract. Rheumatol. 3, 552-560 (2007).
26. Geisslinger, G., Menzel, S., Wissel, K. & Brune, K. Single dose pharmacokinetics of different formulations of ibuprofen and aspirin. Drug Invest 5, 238-242 (1993).
27. Fulkerson, J. P & Folcik, M. A. Analgesia following arthroscopic surgery: comparison of diflunisal and acetaminophen with codeine. Arthroscopy 2, 108-110 (1986).
28. Werner, U. et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin. Pharmacol. Ther. 74, 130-137 (2003).
29. Laska, E. M. et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin. Pharmacol. Ther. 40, 1-7 (1986).
30. Farkouh, M. E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364, 675-684 (2004).
31. Stüber, W. et al. Untersuchungen zur Bioverfügbarkeit von Diclofenac-Natrium aus einer neu entwickelten magensaftresistenten Pellet-Zubereitung. Pharm. Ztg 133, 29-35 (1988).
32. Colombo, G., Giombini, A., Pamich, T, Peruzzi, E. & Pisati, R. Diclofenac dispersible provides superior analgesia with faster onset of action compared to naproxen granular in patients with acute, painful, minor sports injuries. J. Sports Med. Phys. Fitness 37, 228-233 (1997).
33. Griffin, M. R. et al. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol. Drug Saf. 13, 339-343 (2004).
34. Roumie, C. L., Arbogast, P G., Mitchel, E. F. Jr & Griffin, M. R. Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often nappropriate and potentially dangerous. J. Gen. Intern. Med. 20, 879-883 (2005).
35. Renner, B. et al. Absorption and distribution of etoricoxib in plasma, CSF and wound tissue in patients following hip surgery-a pilot study. Naunyn-Schmiedeberg's Arch. Pharmacol. 381, 127-136 (2010).
36. Malmstrom, K. et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo-and active comparator-controlled dose-ranging study. Clin. Ther. 26, 667-679 (2004).
37. Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004).
38. Brune, K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr. Med. Res. Opin. 23, 2985-2995 (2007).
39. Brune, K. & Furst, D. E. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology (Oxford) 46, 911-919 (2007).
40. Day, R. O., McLachlan, A. J., Graham, G. G. & Williams, K. M. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin. Pharmacokinet. 36, 191-210 (1999).
41. Graf, P, Glatt, M. & Brune, K. Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue. Experientia 31, 951-953 (1975).
42. Dutta, S. K., Basu, S. K. & Sen, K. K. Binding of diclofenac sodium with bovine serum albumin at different tuemperatures, pH and ionic strengths. Indian J. Exp. Biol. 44, 123-127 (2006).
43. Fowler, P D., Shadforth, M. F., Crook, P R. & John, V. A. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur. J. Clin. Pharmacol. 25, 389-394 (1983).
44. Doyle, M. J., Eichhold, T. H., Loomans, M. E., Farmer, R. w. & Kelm, G. R. Comparison of tebufelone distribution in rat blood plasma and nflamed and noninflamed tissues following peroral and intravenous administration. J. Pharm. Sci. 82, 847-850 (1993).
45. Schweitzer, A., Hasler-Nguyen, N. & Zijlstra, J. Preferential uptake of the non steroid anti-nflammatory drug diclofenac into inflamed tissues after a single oral dose in rats. BMC Pharmacol. 9, 5 (2009).
46. Elmquist, w. F., Chan, K. K. & Sawchuk, R. J. Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm. Res. 11, 1689-1697 (1994).
47. Scott, G. et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin. Pharmacokinet. 43, 467-478 (2004).
48. Schrör, K., Mehta, P & Mehta, J. L. Cardiovascular risk of selective cyclooxygenase-2 inhibitors. J. Cardiovasc. Pharmacol. Ther. 10, 95-101 (2005).
49. McAdam, B. F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA 96, 272-277 (1999).
50. Brune, K., Rainsford, K. D. & Schweitzer, A. Biodistribution of mild analgesics. Br. J. Clin. Pharmacol. 110 (Suppl. 2), 279S-284S (1980).
51. Bianchi, M., Broggini, M., Balzarini, P, Franchi, S. & Sacerdote, P Effects of nimesulide on pain and on synovial fluid concentrations of substance P, nterleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J. Clin. Pract. 61, 1270-1277 (2007).
52. Maier, T J. et al. Cellular membranes function as a storage compartment for celecoxib. J. Mol. Med. 87, 981-993 (2009).
53. Brune, K. & Alpermann, H. Non-acidic pyrazoles: nhibition of prostaglandin production, carrageenan edema and yeast fever. Agents Actions 13, 360-363 (1983).
54. Tatsuo, M. A. et al. Analgesic and antiinflammatory effects of dipyrone in rat adjuvant arthritis model. Inflammation 18, 399-405 (1994).
55. Hinz, B., Cheremina, O. & Brune, K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 22, 383-390 (2008).
56. Hinz, B. et al. Dipyrone elicits substantial nhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J. 21, 2343-2351 (2007).
57. Boardman, P L. & Hart, F. D. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. BMJ 4, 264-268 (1967).
58. Ring, E. F., Collins, A. J., Bacon, P A. & Cosh, J. A. Quantitation of thermography in arthritis using multi-isothermal analysis. II. Effect of nonsteroidal anti-inflammatory therapy on the thermographic index. Ann. Rheum. Dis. 33, 353-356 (1974).
59. Ouellet, M. & Percival, M. D. Mechanism of acetaminophen inhibition of cyclooxygenase soforms. Arch. Biochem. Biophys. 387, 273-280 (2001).
60. Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J. & Oates, J. A. Determinants of the cellular specificity of acetaminophen as an nhibitor of prostaglandin H2 synthases. Proc. Natl Acad. Sci. USA 99, 7130-7135 (2002).
61. Mielke, C. H. Jr. Comparative effects of aspirin and acetaminophen on hemostasis. Arch. Intern. Med. 141, 305-310 (1981).
62. Niemi, T. T., Backman, J. T., Syrjälä, M. T., viinikka, L. U. & Rosenberg, P H. Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol. Scand. 44, 69-74 (2000).
63. Munsterhjelm, E. et al. Dose-dependent nhibition of platelet function by acetaminophen in healthy volunteers. Anesthesiology 103, 712-717 (2005).
64. Garcia Rodríguez, L. A. & Hernández-Díaz, S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 3, 98-101 (2001).
65. Rahme, E., Barkun, A., Nedjar, H., Gaugris, S. & watson, D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am. J. Gastroenterol. 103, 872-882 (2008).
66. Hinz, B. et al. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing? Ann. Rheum. Dis. 68, 289-291 (2009).
67. Hammett, R. Urgent advice regarding management of patients taking lumiracoxib (Prexige). Australian Government Department of Ageing and Therapeutic Goods Administration [online], www.tga.gov.au/alerts/prexige.htm (2007).
68. Capone, M. L. et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471 (2004).
69. Kearney, P M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302-1308 (2006).
70. Goldstein, J. L. et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment. Pharmacol. Ther. 20, 527-538 (2004).
71. Chan, F. K. et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med. 347, 2104-2110 (2002).
72. Lai, K. C. et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am. J. Med. 118, 1271-1278 (2005).
73. Goldstein, J. L. et al. video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 3, 133-141 (2005).
74. Garcia Rodríguez, L. A., Tacconelli, S. & Patrignani, P Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52, 1628-1636 (2008)
75. European Medicines Agency press release. European Medicines Agency recommends restricted use for piroxicam. European Medicines Agency [online], http://www.ema.europa.eu/ pdfs/human/press/pr/26514407en.pdf (2007).
76. Benson, M. D., Aldo-Benson, M. & Brandt, K. D. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin. Arthritis Rheum. 15 (2 Suppl. 1), 65-67 (1985).
77. McCrea, J. D., Telford, A. M., Kaye, C. M. & Boyd, M. W. A comparison of plasma and synovial fluid profiles of standard and controlled-release formulations of ketoprofen in patients with rheumatoid arthritis. Curr. Med. Res. Opin. 10, 73-81 (1986).
78. wagner, J. G., Albert, K. S., Szpunar, G. J. & Lockwood, G. F. Pharmacokinetics of ibuprofen in man Iv: absorption and disposition. J. Pharmacokinet. Biopharm. 12, 381-399 (1984).